ASP Isotopes Inc. (ASPI) FinancialsASPIASP Isotopes Inc.

ASP Isotopes Inc. (ASPI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Specialist isotopes and related services, accounting for 81.0% of total sales, equivalent to $3.39M. Other significant revenue streams include Helium and LNG and Nuclear fuels. Understanding this composition is critical for investors evaluating how ASPI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, ASP Isotopes Inc. maintains a gross margin of 28.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -667.48%, while the net margin is -663.54%. These profitability ratios, combined with a Return on Equity (ROE) of -104.60%, provide a clear picture of how effectively ASPI converts its operational activities into shareholder value.

In the context of the broader market, ASPI competes directly with industry leaders such as PHOE and ORN. With a market capitalization of $338.81M, it holds a significant position in the sector. When comparing efficiency, ASPI's gross margin of 28.89% stands against PHOE's 4.57% and ORN's 10.33%. Such benchmarking helps identify whether ASP Isotopes Inc. is trading at a premium or discount relative to its financial performance.

ASPI's total revenue for Q2 2026 was 5,123,000, showing some growth, but the company has consistently reported negative net income, with Q2 2026 showing a loss of -33,585,000. Gross margin has fluctuated, with a recent figure of 28.89%, indicating some operational challenges.